Pathologically, NK-cell lymphomas are divided into extranodal NK-/T-cell lymphoma, nasal type and aggressive NK-cell leukemia by the WHO classification. Clinically, NK-cell lymphomas can be ...

WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour ...

CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Lymphomas.

If I can master the treatment of lymphoma, I could use the lessons learned to fight other intractable cancers. We’ve also established a new staging system for extranodal NK/T-cell lymphoma ...

EBViNT, which targets Epstein–Barr virus (EBV)-positive cancers, is in phase 2 for the treatment of natural killer/T cell (NK/T cell) lymphoma. This follows a phase 1 study ( Fig. 1) that ...

CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Leukemia.